Topical Treatment for TMJ Arthralgia
Comparison of Topical 1% Diclofenac and Topical 2.5% Hydrocortisone for TMJ Arthralgia
University of the Pacific
90 participants
Jun 1, 2023
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to evaluate the efficacy of topical 2.5% hydrocortisone in TMJ arthralgia. The main questions it aims to answer are: * How does pain reduction compare? * How does improvement in jaw function limitation compare? * How do side effects compare? Participants will * On day 1 be examined and report their pain level and jaw function limitation * On days 1-21, apply their cream four times a day * On day 21, report their pain level, jaw function limitation, compliance with instructions, and side effects. Researchers will compare topical 2.5% hydrocortisone and topical 1% diclofenac to see if efficacy and side effects differ.
Eligibility
Inclusion Criteria1
- Arthralgia of at least 1 TMJ for at least 3 days
Exclusion Criteria6
- Systemic pain condition
- Past adverse reaction to steroid
- Currently taking steroid
- Taken steroid in the past \_\_\_ months
- Muscle relaxants (may start after study is complete)
- New night guard during study, or within 1 month of start of study (may start after study is complete)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Applied four times daily to TMJ with arthralgia
Applied four times daily to TMJ with arthralgia
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05816226